Abstract
It has come to the attention of the authors that Table 5 was not included in Epigenetics Volume 7, Issue 3 in the manuscript: Lepeule J, Baccarelli A, Tarantini L, Motta V, Cantone L, Litonjua AA, et al. Gene promoter methylation is associated with lung function in the elderly: The normative aging study. Epigenetics 2012; 7:261-9.
The citation for Table 5 should have appeared on p. 264, “Sensitivity analyses. The sensitivity analyses including participants with chronic lung diseases showed similar associations between lung function and DNA methylation as the main analyses, with only slight variations in significance (Table 5).”
It has come to the attention of the authors that Table 5 was not included in Epigenetics Volume 7, Issue 3 in the manuscript: Lepeule J, Baccarelli A, Tarantini L, Motta V, Cantone L, Litonjua AA, et al. Gene promoter methylation is associated with lung function in the elderly: The normative aging study. Epigenetics 2012; 7:261-9.
Table 5 for this manuscript is published here:
The citation for Table 5 should have appeared on p. 264, “Sensitivity analyses. The sensitivity analyses including par-ticipants with chronic lung diseases showed similar associations between lung function and DNA methylation as the main analy-ses, with only slight variations in significance (Table 5).”
Table 5. Percent change in lung function associated* with an interquartile range decrease in gene-specific DNA methylation (percentage of 5-methylcytosine), in 756 men participating to the Normative Aging Study, Boston, 1999-2006.
| Gene | n obs./n subjects | FVC |
FEV1 |
FEV1/FVC† |
MMEF |
||||
|---|---|---|---|---|---|---|---|---|---|
| % | p value | % | p value | % | p value | % | p value | ||
| CRAT |
949/599 |
-1.70 |
0.02 |
-2.28 |
<10-2 |
-0.43 |
0.09 |
-1.74 |
0.24 |
| F3 |
895/583 |
-2.61 |
<10-4 |
-2.02 |
<10-2 |
0.39 |
0.07 |
1.35 |
0.28 |
| GCR |
853/550 |
-1.00 |
0.08 |
-1.07 |
0.09 |
-0.05 |
0.82 |
-0.72 |
0.54 |
| ICAM |
772/522 |
0.63 |
0.35 |
1.57 |
0.05 |
0.65 |
0.01 |
4.56 |
<10-2 |
| IFNg |
983/611 |
1.01 |
0.14 |
1.37 |
0.07 |
0.28 |
0.25 |
3.05 |
0.03 |
| IL6 |
992/607 |
1.51 |
0.03 |
2.26 |
<10-2 |
0.49 |
0.05 |
3.42 |
0.02 |
| iNOS |
648/456 |
-1.63 |
0.06 |
-1.75 |
0.07 |
-0.07 |
0.83 |
-0.41 |
0.83 |
| OGG1 |
629/450 |
-1.03 |
0.13 |
-1.17 |
0.14 |
-0.04 |
0.88 |
-0.08 |
0.96 |
| TLR2 | 828/538 | -2.03 | <10-3 | -2.31 | <10-3 | -0.22 | 0.32 | -3.47 | <10-2 |
Results were adjusted for age (continuous), race (white/black), log (height), standardized weight (linear and quadratic term), % neutrophils, % leucocytes, education level (<12, 12, 13-15, >15 y), smoking status (former/current/never), cumulative smoking (continuous), season of the medical exam (indicator variable), day of the week, corticosteroids (Y/N), sympathomimetic alpha and beta (Y/N), anticholinergics (Y/N), methacholine challenge test (Y/N), asthma (Y/N), chronic bronchitis (Y/N), emphysema (Y/N). †Absolute change in FEV1/FVC.
Footnotes
Previously published online: www.landesbioscience.com/journals/epigenetics/article/20942
